A major advantage has landed! Senapali was approved by the European Medicines Agency, Yingpai Pharmaceutical-B (07630) closed with a sharp rise of 15.51%

Zhitong Finance learned that on September 18, the innovative pharmaceutical company Yingpai Pharmaceutical-B (07630) showed a clear upward trend and closed at HK$13.03 throughout the day, up HK$1.75 from the previous trading day, or 15.51%. The stock opened today at HK$11.37, hitting an intraday high of HK$14.24, with a full day trading volume of 21.1574 million shares, with a turnover of HK$278 million and a total market value of HK$3.68 billion.

According to the news, today's big advantage came to fruition: On September 18, Yingpai Pharmaceutical and global pharmaceutical company Pharmanovia jointly announced that the European Medicines Agency (EMA) Commission for Human Medicines (CHMP) has passed a positive opinion recommending approval (MA) for Sepalna® (Senapali) for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. After approval of the CHMP proposal, Senapali will be submitted to the European Commission for a final decision. Once approved by the European Commission, Senapali will be approved for sale in all EU member states and European Economic Area countries.

Yingpai Pharmaceuticals and Pharmanovia reached an exclusive cooperation in July 2026. Yingpai Pharmaceuticals granted Pharmanovia the exclusive right to manufacture, develop and commercialize senapalil in 66 countries (including all 27 EU member states, as well as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and Middle East and North Africa countries) for the maintenance of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

In addition, Yingpai Pharmaceutical was recently included in the Hong Kong Stock Exchange list. Southbound capital can be directly traded, and market attention continues to increase. According to market analysts, emotional recovery in the innovative drug sector is compounded by the implementation of the international milestone of the approval of Senapali by the European Medicines Agency, compounding multiple benefits such as the inclusion of Hong Kong Stock Connect and the release of domestic products, driving active capital allocation.